362
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Vision Threatening Raised Intracranial Pressure Associated with Recreational Nitrous Oxide Use

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Received 31 Oct 2023, Accepted 22 Dec 2023, Published online: 26 Jan 2024

References

  • Randhawa G, Bodenham A. The increasing recreational use of nitrous oxide: history revisited. Br J Anaesth. 2016;116(3):321–324. doi:10.1093/bja/aev297.
  • van Amsterdam J, Nabben T, van den Brink W. Recreational nitrous oxide use: prevalence and risks. Regul Toxicol Pharmacol. 2015;73(3):790–796. doi:10.1016/j.yrtph.2015.10.017.
  • Lan SY, Kuo CY, Chou CC, et al. Recreational nitrous oxide abuse related subacute combined degeneration of the spinal cord in adolescents – a case series and literature review. Brain Dev. 2019;41(5):428–435. doi:10.1016/j.braindev.2018.12.003.
  • Mollan SP, Davies B, Silver NC, et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry. 2018;89(10):1088–1100. doi:10.1136/jnnp-2017-317440.
  • Jevtović-Todorović V, Todorović SM, Mennerick S, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med. 1998;4(4):460–463. doi:10.1038/nm0498-460.
  • Gillman MA, Lichtigfeld FJ. Clinical role and mechanisms of action of analgesic nitrous oxide. Int J Neurosci. 1998;93(1–2):55–62. doi:10.3109/00207459808986412.
  • Winstock AR, Ferris JA. Nitrous oxide causes peripheral neuropathy in a dose dependent manner among recreational users. J Psychopharmacol. 2020;34(2):229–236. doi:10.1177/0269881119882532.
  • Mair D, Paris A, Zaloum SA, et al. Nitrous oxide-induced myeloneuropathy: a case series. J Neurol Neurosurg Psychiatry. 2023;94(9):681–688. doi:10.1136/jnnp-2023-331131.
  • Layzer RB, Fishman RA, Schafer JA. Neuropathy following abuse of nitrous oxide. Neurology. 1978;28(5):504–506. doi:10.1212/wnl.28.5.504.
  • Phirman JR, Shapiro HM. Modification of nitrous oxide-induced intracranial hypertension by prior induction of anesthesia. Anesthesiology. 1977;46(2):150–151. doi:10.1097/00000542-197702000-00017.
  • Henriksen HT, Jörgensen PB. The effect of nitrous oxide on intracranial pressure in patients with intracranial disorders. Br J Anaesth. 1973;45(5):486–492. doi:10.1093/bja/45.5.486.
  • Mollan SP, Spitzer D, Nicholl DJ. Raised intracranial pressure in those presenting with headache. BMJ. 2018;363:k3252. doi:10.1136/bmj.k3252.
  • Mollan SP, Tahrani AA, Sinclair AJ. The potentially modifiable risk factor in idiopathic intracranial hypertension: body weight. Neur Clin Pract. 2021;11(4):e504–e507. doi:10.1212/CPJ.0000000000001063.
  • Mollan SP, Ball AK, Sinclair AJ, et al. Idiopathic intracranial hypertension associated with iron deficiency anaemia: a lesson for management. Eur Neurol. 2009;62(2):105–108. doi:10.1159/000222781.
  • Reynolds G, Epps S, Huntley A, Atan D. Micronutrient deficiencies presenting with optic disc swelling associated with or without intracranial hypertension: a systematic review. Nutrients. 2022;14(15):3068. doi:10.3390/nu14153068.
  • Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med. 1988;318(26):1720–1728. doi:10.1056/NEJM198806303182604.
  • Biousse V, Rucker JC, Vignal C, Crassard I, Katz BJ, Newman NJ. Anemia and papilledema. Am J Ophthalmol. 2003;135(4):437–446. doi:10.1016/s0002-9394(02)02062-7.
  • Yetgin S, Derman O, Dogan M. A pediatric patient with recurrent pseudotumor cerebri and vitamin B12 deficiency. Pediatr Hematol Oncol. 2006;23(1):39–43. doi:10.1080/08880010500313322.